Table 2.
Comparison of Chromosomal Abnormalities Detected by Conventional Cytogenetic Assays and aCGH in CLL Samples
| Case | G-banding | CLL FISH panel | aCGH result | Gain/loss | Size (Mb) | Comparison |
|---|---|---|---|---|---|---|
| CLL-1 | 46,XY,del(11)(q13q23), del(13)(q14q22)[3]/46,XY[27] | nuc ish(ATMx1)[212/500] | 2p16.1p15(58,239,976–63,119,015)x3 | G | 4.88 | Additional finding |
| nuc ish(D13S319x1)[224/500] | 11q21q24.2(95,824,986–123,972,410)x1 | L | 28.15 | Consistent | ||
| 13q14.2q22.2 (46,457,567–75,032,954)x1 | L | 28.58 | Consistent | |||
| CLL-2 | 46,XY,der(7)t(7;12) (p13;q13),del(11) (q13q23)[6]/46,XY[38] | nuc ish(ATMx1)[395/500] | 7p22.3p14.3(298,857–32,463,740)x1 | L | 32.17 | Consistent |
| 11q14.1q23.2(78,505,139–114,526,789)x1 | L | 36.02 | Consistent | |||
| 12q15q24.33 (66,153,647–132,274,021)x3 | G | 66.12 | Consistent | |||
| CLL-3 | Negative | No copy number gain or loss | Consistent | |||
| CLL-4 | nuc ish(CEP12x3)[119/500] | 9p21.3p21.2(20,141,095–25,769,281)x1 | L | 5.63 | Additional finding | |
| nuc ish(D13S319x0)[113/500] | 11q13.4q25(74,235,693–134,203,983)x3 | G | 59.97 | Additional finding | ||
| nuc ish(TP53x1)[27/500] | 12p13.33q24.33(59,839–132,274,021)x3 | G | 132.21 | Consistent | ||
| 13q14.2q14.3 (47,634,299–50,360,303)x1 | L | 2.73 | Consistent | |||
| 15q15.2q22.2(40,843,438–61,125,198)x3 | G | 20.28 | Additional finding | |||
| 15q22.2q22.32(61,203,747–63,277,549)x1 | L | 2.073 | Additional finding | |||
| 15q22.32q26.3(63,349,209–97,997,129)x3 | G | 34.65 | Additional finding | |||
| 17p13.3p11.2 (572,226–16,467,786)x1 | L | 15.89 | Consistent | |||
| CLL-5 | nuc ish(D13S319x1)[80/500] | 1q25.2(176,463,562–177,342,180)x1 | L | 0.88 | Additional finding | |
| 13q14.2q14.3(48,811,812–51,260,640)x1 | L | 2.45 | Consistent | |||
| 17q11.2(25,206,771–27,341,867)x1 | L | 2.14 | Additional finding | |||
| CLL-6 | nuc ish(D13S319x1)[79/200] | 4q21.21q34.1(80,064,046–175,930,298)x3 | G | 95.87 | Additional finding | |
| 11q25 (130,802,834–133,537,033)x1 | L | 2.73 | Additional finding | |||
| 13q14.3(49,556,169–50,302,345)x1 | L | 0.75 | Consistent | |||
| CLL-7 | nuc ish(D13S319x1)[313/500] (D13S319x0)[146/500] | 13q14.12q21.33 (45,186,614–68,407,441)x1 | L | 23.22 | Consistent | |
| CLL-8 | 47,XY,+12[3]/46,XY[1] | nuc ish(CEP12x3)[130/200] | 8p23.3p23.1(510,912–12,646,458)x1 | L | 12.14 | Additional finding |
| nuc ish(TP53x1)[69/200] | 8q22.1q24.3(94,588,642–146,024,209)x3 | G | 51.44 | Additional finding | ||
| 12p13.33q24.33(59,839–132,274,021)x3 | G | 132.21 | Consistent | |||
| Not detected | ||||||
| CLL-9 | nuc ish(ATMx1)[106/200] | 2p25.3p11.2 (56,097–86,913,786)x3 | G | 86.86 | Additional finding | |
| nuc ish(D13S319x1)[122/200] | 8q24.13(125,141,042–126,067,964)x1 | L | 0.93 | Additional finding | ||
| 11q21q23.2(95,896,516–116,055,830)x1 | L | 20.16 | Consistent | |||
| 13q14.2q14.3 (47,747,097–50,570,768)x1 | L | 2.82 | Consistent | |||
| CLL-10 | nuc ish(D13S319x1)[105/200] (D13S319x0)[22/200] | 13q14.3 (49,393,673–50,360,303)x1 | L | 0.97 | Consistent | |
| CLL-11 | nuc ish(ATMx1)[188/200] | 11q14.1q23.3(82,248,677–116,410,246)x1 | L | 34.16 | Consistent | |
| nuc ish(D13S319x1)[176/200] | 13q14.3(49,393,673–50,428,576)x1 | L | 1.04 | Consistent | ||
| CLL-12 | Negative | No copy number gain or loss | Consistent | |||
| CLL-13 | Negative | No copy number gain or loss | Consistent | |||
| CLL-14 | nuc ish(CEP12x3)[140/300] | 12p13.33q24.33(59,839–132,274,021)x3 | G | 132.21 | Consistent | |
| nuc ish(D13S319x1)[141/300] | 13q14.3(49,488,278–50,308,235)x1 | L | 0.82 | Consistent | ||
| 19p13.3q13.43(588,365–62,792,815)x3 | G | 62.20 | Additional finding | |||
| 22q11.1q13.33(15,659,961–49,270,055)x3 | G | 33.61 | Additional finding | |||
| CLL-15 | Negative | 2q36.3q37.1(230,519,517–231,293,094)x1 | L | 0.77 | Additional finding | |
| CLL-16 | nuc ish(D13S319x1)[147/200] | 13q14.3 (49,393,673–50,506,276)x1 | L | 1.11 | Consistent | |
| CLL-17 | Negative | No copy number gain or loss | ||||
| Total abnormal event | Combined: 21 | 37 |
G, gain; L, loss.